This study investigates whether dupilumab, a Type 2 inflammation-blocking agent commonly used to treat allergic diseases, is associated with an increased risk of developing Type 1 diseases in children. Using the PEDSnet electronic health record network, researchers conducted a multicenter retrospective cohort study involving children aged 6-17 with asthma and/or atopic dermatitis, comparing those treated with dupilumab to those untreated and non-atopic children. The primary outcome was the diagnosis of Type 1 diseases, including conditions affecting the skin, endocrine, gastrointestinal, and other systems.
The results showed that while overall rates of Type 1 disease diagnoses were low, dupilumab-treated children had a 1.9 times higher risk of developing Type 1 diseases within 4 years of treatment. Despite this increased risk, the findings suggest the need for further prospective studies to confirm the accuracy of these diagnoses and better understand the long-term side effects of dupilumab.
Funding Source:
Participating PEDSnet Sites:
- Cincinnati Children’s Hospital Medical Center
- Children’s Hospital of Philadelphia
- Children’s National Hospital
- Ann & Robert H. Lurie Children’s Hospital of Chicago
- Nationwide Children’s Hospital
- Seattle Children’s Hospital
- Nemours Children’s Health
- Texas Children’s Hospital
Study Investigator:
Vasoactive Selection in Pediatric Septic Shock and the Use of Cardiac Point-of-Care Ultrasound: A Retrospective Registry Analysis Across Multicenter Pediatric Emergency Medicine and Pediatric Critical Care
Pediatric septic shock requires rapid recognition of cardiovascular failure and timely treatment to restore adequate tissue perfusion. Vasoactive medications are central to management, yet considerable uncertainty remains regarding the optimal first‑line agent. Although guidelines recommend tailoring vasoactive choice to a…
Childhood Neighborhood Exposures and Pediatric Multiple Sclerosis
Question 1: How can we identify children with MS using ICD-10 codes in the PEDSnet dataset Question 2: How do neighborhood exposures influence the risk of pediatric MS development Aim 1: Validate a computable phenotype to identify pediatric MS. Aim…
Preventing Suicide among Sexual and Gender Diverse Youth
Suicide is the second leading cause of death among young adults in the United States. Sexual and gender diverse young adults (SGDYA) are at particularly high risk. SGDYA includes individuals who are lesbian, gay, bisexual, transgender, queer, or of another…